secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001193125-24-271578
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
- Gross proceeds expected ~$350M before expenses; funds to advance clinical pipeline and for general purposes
- Underwriters granted 30-day option to purchase up to additional 833,333 shares
- Offering expected to close Dec 6, 2024; joint book-runners: BofA, TD Cowen, Stifel, Cantor, William Blair

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312524271578/0001193125-24-271578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312524271578/d877731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-271578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer